Back
Fate Therapeutics, Inc. Stock Predictions
Missed $0.81? RAD Intel Now Open at $0.85/Share
DISCLOSURE: This is a paid advertisement for RAD Intel's Reg A offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks at invest.radi
Sell
29
FATE
Fate Therapeutics, Inc.
Last Price:
$1.08
Seasonality Move:
30.36%
7 Day Trial
ALL ACCESS PASS
$
7
AI Powerhouse Raises Price - But Room Remains
DISCLOSURE: This is a paid advertisement for RAD Intel's Reg A offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks at invest.radiFate Therapeutics, Inc. Stock Forecast
-
Is Fate Therapeutics, Inc. Stock Undervalued?The current Fate Therapeutics, Inc. [FATE] share price is $1.08. The Score for FATE is 29, which is 42% below its historic median score of 50, and infers higher risk than normal.
-
FATE is currently trading in the 20-30% percentile range relative to its historical Stock Score levels.
Will Fate Therapeutics, Inc. Stock Go Up Next Year?
Data Unavailable
Fate Therapeutics, Inc. Stock Rating
Data Unavailable
Fate Therapeutics, Inc. Stock Price History
Stock Information
Stock Info
Exchange:
NASDAQ
Country:
United States
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
fatetherapeutics.com
52-Week Data
52-Week High:
2.93
52-Week Low:
0.66
Prediction Charts
Market Cap:
124.6M
Price in USD:
1.08
Volume:
739.8K
Beta:
1.86
Technical Analysis
SMA50:
1.25
SMA100:
1.16
SMA200:
1.14
52-Wk Change:
-54.62%
Stock Predictions
-
Is Fate Therapeutics, Inc. stock public?Yes, Fate Therapeutics, Inc. is a publicly traded company.
-
What is the Fate Therapeutics, Inc. stock quote today?The Fate Therapeutics, Inc. stock price is 1.08 USD today.
-
How to buy Fate Therapeutics, Inc. stock online?You can buy Fate Therapeutics, Inc. shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
14-Day Historical Data
| Date | Opening | Closing | Minimum | Maximum |
|---|---|---|---|---|
| Nov-17 | 0.98 | 0.97 | 1.06 | 0.96 |
| Nov-18 | 0.99 | 1.02 | 1.03 | 0.96 |
| Nov-19 | 0.98 | 1.05 | 1.08 | 0.98 |
| Nov-20 | 1.06 | 1.00 | 1.11 | 0.99 |
| Nov-21 | 1.00 | 1.03 | 1.05 | 0.97 |
| Nov-24 | 1.05 | 1.08 | 1.10 | 1.05 |
| Nov-25 | 1.10 | 1.06 | 1.13 | 1.04 |
| Nov-26 | 1.08 | 1.10 | 1.10 | 1.05 |
| Nov-28 | 1.10 | 1.14 | 1.16 | 1.10 |
| Dec-1 | 1.14 | 1.03 | 1.15 | 1.02 |
| Dec-2 | 1.04 | 1.01 | 1.06 | 1.00 |
| Dec-3 | 1.00 | 1.08 | 1.09 | 0.99 |
| Dec-4 | 1.07 | 1.10 | 1.12 | 1.05 |
| Dec-5 | 1.08 | 1.08 | 1.12 | 1.06 |
Fate Therapeutics, Inc. Earnings
Data Unavailable
Fate Therapeutics, Inc. Forecast Revenue Growth
Data Unavailable
-
Analysts estimate an earnings increase this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, an increase this year of $0.43 per share, and a decrease next year of $0.01 per share.
* Fate Therapeutics, Inc. stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.